Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-19	US$0.000000	-	60

Delayed Quote OTC Markets

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets 12:25:32 2026-06-01 EDT			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	+9,900.00%

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 86.72K 81.1K 74.25K 139K 9.69M 141K 958K 373K 4.86M 380K 372K 16.1M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.7M 9.08M 8.31M 15.6M 1.08B 15.81M 107M 41.8M 544M 42.55M 41.62M 1.8B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
25-10-14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-08-15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
25-04-30	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
25-04-29	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
24-11-15	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
24-10-17	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
24-10-15	Top Midday Decliners	MT
24-10-14	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
24-09-27	Top Midday Decliners	MT
24-09-24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24-09-24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

23-09-21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
23-09-21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
23-09-21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
23-03-24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

24-11-22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24-10-24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24-10-24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
24-10-15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
24-10-15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		4,665.6
5 years	0		10,713.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	2018-12-31
Michael Golembiewski DFI	Director of Finance/CFO	54	2021-08-31
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/29/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
1/12/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%
1/12/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	+9,900.00%	-100.00%	136
WUXI APPTEC CO., LTD.	-3.00%	+2.27%	+77.60%	+109.33%	72.12B
ARGENX SE	+1.90%	+23.53%	+56.60%	+97.76%	65.85B
BIONTECH SE	+5.12%	+25.22%	+5.24%	-0.82%	29.28B
INSMED INCORPORATED	+0.55%	+1.64%	-5.15%	+471.68%	27.47B
WUXI BIOLOGICS (CAYMAN) INC.	+2.74%	+12.98%	+62.84%	+28.14%	26.7B
GENMAB A/S	+0.47%	+6.12%	+36.66%	-13.79%	20.06B
PHARMAESSENTIA CORPORATION	+1.82%	-6.67%	+247.46%	+393.10%	18.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.94%	+3.36%	+18.55%	+532.94%	16.4B
EXELIXIS, INC.	+0.73%	+5.54%	+39.71%	+153.07%	13.4B
Average	+991.13%	+7.53%	+1,043.95%	+167.14%	28.95B
Weighted average by Cap.	+0.74%	+9.48%	+59.05%	+157.80%

	2022	2023
Net sales	-	2.2 1.89 1.76 1.62 3.03 210.85 3.07 20.85 8.12 105.81 8.27 8.09 350.14
Net income	-73.53M -62.97M -58.89M -53.91M -101M -7.04B -103M -696M -271M -3.53B -276M -270M -11.69B	-37.88M -32.44M -30.34M -27.77M -52.14M -3.63B -52.84M -358M -140M -1.82B -142M -139M -6.02B
Net Debt	4.59M 3.93M 3.68M 3.36M 6.32M 439M 6.4M 43.42M 16.92M 220M 17.23M 16.85M 729M	11.23M 9.62M 9M 8.23M 15.46M 1.08B 15.67M 106M 41.42M 539M 42.17M 41.25M 1.79B